In Review: Last week, PCMA submitted a Motion to Intervene to the OIR regarding Clinical Specialty Infusions of Dallas, LLC’s petition to the OIR for a declaratory statement on the department’s interpretation of provisions contained in SB 1550 that address specialty pharmacy accreditation and network standards. Next, the OIR will need to schedule an informal hearing sometime within the next 30 days, at which point each side will further address its arguments.

Additionally, TransparencyRx has filed three petitions with the state Division of Administrative Hearings requesting a determination of invalidity of an agency statement as unadopted rules. The three cases focus on the market conduct exams and the OIR’s lack of formal rules outlining requirements and standards for the exams, and more. The hearing is scheduled for September 24 and 25 at 9 a.m. EST.

If you have any questions, please contact Connor Rose at crose@pcmanet.org.